glp 1 parkinson's GLP-1 drug shows little benefit for people with disease | UCL News Incretin and insulin signaling as
Description
The base line is, if too much of nutrition intake, particularly protein, is cut back, the body will break down muscle for fuel
As Shreehas Tambe, Chief Executive Officer and Managing Director of Biocon Biologics Limited, noted regarding demand and growth potential for GLP-1 therapies, There will be a requirement for significantly higher volumes and Biocons fermentation capability will give us a significant advantage. India leads with a CAGR of 8.4%, driven by a large diabetic population and increasing demand for effective treatments
Abu EK, O Ofori A, B Boadi-Kusi S, et al
doi: 10.2174/1381612033454775 26 BaggioLLHuangQBrownTJDruckerDJBaggioLLHuangQet al
And while we shouldnt reject a therapy just because its potent, we also shouldnt race ahead without asking: potent enough for whatand for how long
Since then, its use has been expanded to other conditions that will be discussed below
